Disc Medicine reports positive Phase 2 bitopertin data in EPP: PPIX down >40%, sunlight tolerance up >80-fold

Disc Medicine, Inc.

Mean reduction of whole-blood PPIX >40% in dose-dependent, sustained manner across 15 patients.
Two patients with longest follow-up: >80-fold (20 mg) and >200-fold (60 mg) increase in sunlight tolerance without prodrome.
Average weekly sunlight exposure rose from 344 min at baseline to 1,200 min at Week 24; time to prodrome increased >7-fold.
Patient-reported phototoxic reactions reduced 96% vs. baseline; all 10 patients at Day 43 reported disease much/a little better on PGIC.
Bitopertin well-tolerated: no serious AEs, no discontinuations, no grade >1 AEs, no meaningful hemoglobin changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.